Expanded Pharmacology Services to Help Accelerate Your Non-GLP Efficacy Screening
May 7, 2009 – In addition to verifying safety, determining the effectiveness of a specific test article for its intended use in relevant animal models of human disease is one of the most important aspects of lead candidate selection. To help assist your efficacy evaluations, we have recently expanded our early research and proof-of-principle pharmacology services.
Our scientific team can help you select the appropriate models and assays for your test article, as well as design new models that are tailored to meet the specific needs of your discovery program. We offer both rodent and nonrodent pharmacology models to advance your lead candidate optimization in the following key therapeutic areas:
Oncology
In vivo models include human tumor xenograft, syngeneic, metastatic, orthotopic, and genetically engineered models. These models are augmented with the use of preclinical imaging technologies (such as PET, MRI, CT, and bioluminescence) and expertise in IC50 determination, combination chemotherapy, radiation therapy, angiogenesis, biomarker, and pharmacodynamic assessment.
Metabolic Diseases
Efficacy screening can be conducted in models of diabetes mellitus, obesity, hyperlipidemia, and renal diseases, among others.
Cardiovascular Diseases
Compound efficacy testing is performed in models of atherosclerosis and hypertension.
Respiratory Diseases
Efficacy models include asthma, airway hyperresponsiveness, and chronic obstructive pulmonary disease.
Inflammatory Diseases
Efficacy testing is available in models of rheumatoid arthritis, experimental allergic encephalitis, asthma, delayed type hypersensitivity, peritonitis, LPS-induced cytokine release, T cell-dependent antibody response, and sponge granuloma, among others.
Central Nervous System Disorders
Models include experimental allergic encephalitis, epilepsy, pain, locomotor, cognitive, and ocular disorders.
Bone and Cartilage Diseases
Models span from osteoporosis and osteoarthritis to rheumatoid arthritis.
To learn more about how our non-GLP efficacy, pharmacokinetic, and toxicity evaluations can help advance your lead candidate selection, please contact us at 1.877.CRIVER.1 (1.877.274.8371) or askcharlesriver@crl.com, or visit www.criver.com/info/discoveryservices.